Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Holdings Trimmed by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 503,045 shares of the biopharmaceutical company’s stock after selling 22,258 shares during the quarter. Loomis Sayles & Co. L P owned 0.39% of Alnylam Pharmaceuticals worth $118,372,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ALNY. Larson Financial Group LLC raised its stake in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $33,000. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. True Wealth Design LLC boosted its holdings in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $45,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on ALNY shares. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research report on Friday, March 21st. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a report on Friday, March 21st. Royal Bank of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday, March 21st. HC Wainwright increased their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $312.30.

Alnylam Pharmaceuticals Trading Down 4.2 %

NASDAQ:ALNY opened at $269.21 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $34.85 billion, a PE ratio of -124.06 and a beta of 0.39. The business’s 50-day simple moving average is $258.98 and its 200-day simple moving average is $260.32. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.